Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
about
Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.
P2860
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@en
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@nl
type
label
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@en
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@nl
prefLabel
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@en
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@nl
P2093
P2860
P1476
Almorexant effects on CYP3A4 a ...... simvastatin and atorvastatin.
@en
P2093
Jasper Dingemanse
Matthias Hoch
Petra Hoever
Rudolf Theodor
P2860
P2888
P304
P356
10.1007/S00228-012-1470-8
P577
2013-01-20T00:00:00Z